<DOC>
	<DOCNO>NCT02172430</DOCNO>
	<brief_summary>The objective study investigate long-term safety Ba 79 BR ( tiotropium ) powder inhalation patient COPD use oxitropium bromide ( Tersigan ) comparator . Secondarily , long-term efficacy Ba 679 BR also investigate</brief_summary>
	<brief_title>Comparison Tiotropium Inhalation Capsules Oxitropium Metered Dose Inhalator ( MDI ) Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Oxitropium</mesh_term>
	<criteria>The patient COPD ( chronic bronchitis , emphysema ) whose symptom stable satisfy follow criterion 1 . Patients FEV1.0 &lt; =70 % predict normal FEV1.0/FVC &lt; =70 % screen test ( The FEV1.0 value also &lt; =70 % predict normal start day administration ( visit 2 ) . ) 2 . Patients smoke history ( &lt; number cigarette smoke day x number smoke year &gt; &gt; =200 . ) 3 . Male female patient age &gt; =40 year old 1 . Patients complicate bronchial asthma , make assessment drug efficacy COPD difficult 2 . Patients use oral corticosteroid medication dose excess equivalent 10 mg/day prednisolon 3 . Patients glaucoma 4 . Patients symptomatic prostatic hypertrophy 5 . Patients hypersensitivity anticholinergic drug powder inhalant 6 . Patients serious complication judge investigator inappropriate subject study 7 . Patients demonstrate clinically problematic abnormal laboratory test value ( general blood test , biochemical test , urinalysis ) . Those show Glutamic Oxaloacetic Transaminase ( GOT ) Glutamic PyruvicTransaminase ( GPT ) twice upper limit normal range , bilirubin 1.25 time creatinine 1.25 time upper limit normal range exclude . 8 . Patients recent history myocardial infarction heart failure ( i.e . within 3 month screen test ) 9 . Patients arrhythmia require treatment drug 10 . Patients concomitant use betablocker prohibit . 11 . Patients begin treatment ACE inhibitor within 1 month screen test 12 . Patients tuberculosis ( currently active ) definite sequela tuberculosis 13 . Patients recent history carcinoma ( exclude basal cell carcinoma ) ( i.e . within past 5 year ) 14 . Patients history cystic fibrosis bronchiectasis 15 . Patients recent onset upper airway infection ( i.e . within 1 month screen test ) 16 . Patients take investigational drug within one month within period six time halflives drug ( whichever longer ) screen test . 17 . Women pregnant may become pregnant , breast feeding 18 . Other , judged investigator inappropriate subject study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>